MyFinsight
Home
Blog
About
Net income
$122M
(87.69%↑ Y/Y)
Other current and
noncurrent liabilities
$73M
(-44.27%↓ Y/Y)
Deferred income taxes
$25M
(257.14%↑ Y/Y)
Stock-based compensation
$11M
(-21.43%↓ Y/Y)
Current inventories
-$4M
(81.82%↑ Y/Y)
Accounts receivable
-$3M
(80.00%↑ Y/Y)
Impairment of tangible and
intangible assets
$2M
Depreciation and
amortization
$2M
(-60.00%↓ Y/Y)
Accrued legal and
settlement expenses
$1M
(101.67%↑ Y/Y)
Amortization of debt issuance
costs
$1M
Impact from foreign
exchange movements
-$1M
(-120.00%↓ Y/Y)
Amortization of right-of-use
assets
$1M
(-80.00%↓ Y/Y)
Net cash provided by
operating activities
$229M
(44.94%↑ Y/Y)
Canceled cashflow
$17M
Net increase in cash
and cash...
$48M
Canceled cashflow
$181M
Other current and
noncurrent assets
$17M
(154.84%↑ Y/Y)
Other
$2M
Sales and maturities
of debt securities
$3M
(-72.73%↓ Y/Y)
Net cash used in
financing activities
-$173M
(-3360.00%↓ Y/Y)
Net cash used in
investing activities
-$8M
(52.94%↑ Y/Y)
Canceled cashflow
$2M
Canceled cashflow
$3M
Cash paid for
repurchases of common stock
$176M
Purchases of property and
equipment
$7M
(-58.82%↓ Y/Y)
Purchases of investments
in debt securities
$3M
(-50.00%↓ Y/Y)
something is missing
-$1M
Back
Back
Cash Flow
indivior-logo-svg
Indivior Pharmaceuticals, Inc. (INDV)
indivior-logo-svg
source: myfinsight.com
Indivior Pharmaceuticals, Inc. (INDV)